39 results about "Pemphigus" patented technology

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

Provided are methods for treating pemphigus using an FcRn antagonist such as efgartigimod. The methods of the invention provide a rapid onset of action to enable early disease control and maintenance of clinical remission, with or without a minimal dose of corticosteroids.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

Disclosed herein is a method of treating pemphigus in a human patient in need thereof, comprising administering to the human patient a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) once daily (QD) or twice daily (BID).

The present invention provides, among other things, improved methods and compositions for treating pemphigus and pemphigoid comprising administering to a subject suffering from pemphigus or pemphigoid an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom of pemphigus or pemphigoid.

The application belongs to the field of biological medicine, and provides an antibody combined with a specific antigen peptide of common pemphigus and application thereof, and the application uses the principle of phage display technology to perform in-vitro affinity screening on a constructed library, combines phages with target antigen Dsg3, elutes non-specific binders, retains phages combined with the antigen closely, and then amplifies the phages and performs multiple rounds of affinity enrichment; multiple rounds of panning are performed, and after 3-5 rounds of screening, phage clones with strong Dsg3 binding capacity and high specificity can be obtained.

The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

Methods for treating bullous pemphigoid in a subject are provided. In one aspect, the methods comprise administering to a subject having bullous pemphigoid one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention belongs to the field of biological medicine, and provides an antibody combined with pemphigus vulgaris specific antigen peptide and application of the antibody. According to the principle of a phage display technology, a constructed library is subjected to in-vitro affinity screening, phages are combined with a target antigen Dsg3, non-specific binders are eluted, the phages tightly combined with the antigen are reserved, and the pemphigus vulgaris specific antigen peptide is obtained. Then, amplifying and carrying out affinity enrichment for multiple rounds; and carrying out multiple rounds of panning, and after 3-5 rounds of screening, obtaining phage clones with strong binding capacity with Dsg3 and high specificity.

The present invention relates to a CXCL8 inhibitor that is useful for the prevention and / or treatment of ocular mucous membrane pemphigoid and / or oral mucous membrane pemphigoid.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

A method of treating a subject suffering from an immune-mediated disease (e.g., IgA nephropathy, primary membranous nephropathy, an antibody-mediated rejection, lupus nephritis, systemic lupus erythematosus (SLE), Graves' Disease, Myasthenia Gravis, Anti-PLA2R positive Membranous Glomerulonephritis (aMN), Pemphigus, Sjögren's syndrome, and / or Anti-NMDA encephalitis) by administering to the subject a regimen of at least five doses of felzartamab and measuring a level of CD19+CD27hiCD38hi plasmablasts, a level of CD19+ B lymphocytes, or levels of CD19+CD27hiCD38hi plasmablasts and CD19+ B lymphocytes in a blood sample taken from the subject.

Disclosed herein are methods for treating pemphigus in a human patient in need thereof comprising administering to the human patient a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) once a day (QD) or twice a day (BID).

The present invention discloses a rabbit hybridoma monoclonal antibody against mouse BP180NC14A, a preparation method, an application, and a hybridoma cell line. The monoclonal antibody is specific for the polypeptide encoded by nucleotides 499-573 in Q07563-1 (i.e., the amino acid sequence shown in SEQ ID No. 1). The beneficial effects of the present invention are embodied in providing a monoclonal antibody against mouse BP180NC14A, its preparation and application, and a rabbit hybridoma cell line producing the monoclonal antibody. These antibodies provide a basis for further clarifying the pathophysiological research of BP180 in skin tissue, and can be used to induce a mouse bullous pemphigoid (BP) model or detect anti-BP180 IgG titers in mice, thus having important application prospects.

The invention belongs to the field of biological medicine, and provides an antibody combined with pemphigus vulgaris specific antigen peptide and application of the antibody. According to the principle of a phage display technology, a constructed library is subjected to in-vitro affinity screening, phages are combined with a target antigen Dsg3, non-specific binders are eluted, the phages tightly combined with the antigen are reserved, and the pemphigus vulgaris specific antigen peptide is obtained. Then, amplifying and carrying out affinity enrichment for multiple rounds; and carrying out multiple rounds of panning, and after 3-5 rounds of screening, obtaining phage clones with strong binding capacity with Dsg3 and high specificity.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a blood fat reducing medicine in preparation of a medicine for treating pemphigus. According to the application disclosed by the invention, the hypolipidemic drug is found to be used for treating pemphigus for the first time, and by analyzing the blood fat of a PV patient, the hypolipidemic metabolism of the patient is found to be abnormal, and the oxidative stress level is related to the classical biomarker level of PV. Lipid-induced oxidative stress was confirmed by in vitro experiments using HaCaT cells treated with serum of PV patients, and it was found that it results in STAT3 activation and mitochondrial dependent apoptosis. ATO intervention can effectively reverse the pathological process: by correcting lipid metabolism disorder, ATO significantly reduces the oxidative stress level, inhibits STAT3 phosphorylation, and reduces the occurrence of mitochondrial dependent apoptosis. The invention discloses an important relationship among lipid disorder, oxidative stress, apoptosis and STAT3 activation in PV, and prompts that statins may become a potential treatment strategy for PV.

The invention provides a medicine for treating or preventing pemphigus. More specifically, the present invention provides a pharmaceutical composition for treating or preventing pemphigus, containing, as an active ingredient, an induced regulatory T cell having at least one characteristic selected from the group consisting of CTLA4 positive, NT5E positive, ITGAE (CD103) positive, AREG positive, CD172g positive, and CD26 positive.

The invention relates to the field of immunology and cell therapy, in particular to application of rTh1 cells in preparation of drugs for preventing or treating allergic diseases or inflammatory diseases, the phenotypes of the rTh1 cells are CD3 (+), CD4 (+), CD25 (-), Foxp3 (-), CXCR5 (-), CCR6 (-), CXCR3 (+), CD73 (+) and cMaf (+), and FR4, PD1 and ICOS are highly expressed. The novel T cell subset rTh1 cell has an immunoregulation function, and has an important value in prevention and treatment of allergic diseases such as food allergy and dust mite allergy, atopic dermatitis, allergic asthma, chronic obstructive pulmonary disease and other Th2-type inflammation related skin diseases such as pemphigus bullosa and urticaria.

The present invention relates to a composition containing an Eclipta prostrata extract-derived compound as an active component for preventing, alleviating or treating pemphigus. The compound of Chemical Formula 1, which is the compound derived from an Eclipta prostrata extract of the present invention, has almost no cytotoxicity and exhibits antioxidant activity (reduction of reactive oxygen species (ROS) generation), and an excellent inhibitory effect on keratinocyte dissociation induced by AK23 (Anti-Desmoglein 3), thereby being able to be usefully used for preventing, alleviating or treating pemphigus.

The present application relates to canine and feline FcRn antagonists comprising canine or feline Fc fragment polypeptides that reduce or block binding of canine or feline FcRn to canine or feline IgG autoantibodies, and the use of these FcRn antagonists in treating canine or feline subjects suffering from autoantibody associated autoimmune disorders, such as pemphigus, bullous pemphigoid, lupus erythematosus, and stomatitis.

To provide a composition for use in a method of treating an IL-4 / IL-13 related disorder.SOLUTION: Provided is a composition for use in a method of treating an eye-related disorder in a subject in need thereof with an anti-interleukin-4 receptor α (anti-IL-4Rα) antibody, wherein the eye-related disorder is selected from dry eye, blepharitis, cicatricial pemphigoid, Mooren's corneal ulcer, Vogt-Koyanagi-Harada syndrome, sympathetic ophthalmia, phacoanaphylaxis endophthalmitis, or a combination thereof, and wherein the method comprises administering a therapeutically effective amount of the anti-IL-4Rα antibody to the subject.SELECTED DRAWING: Figure 2

The present disclosure relates to RIPK2 inhibitors of the formulae (I) or (II) for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and, more specifically, for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease.

The present invention provides a composition comprising a first polypeptide comprising a dimerization domain and a first fragment of an extracellular domain of DSG1 or DSG3 or an analog or derivative thereof, and a second polypeptide comprising a dimerization domain and a second fragment of an extracellular domain of DSG1 or DSG3 or an analog or derivative thereof. Also provided are polypeptides comprising a fragment of the extracellular domain of DSG1 or DSG3 comprising at least one mutation that increases solubility, reduces aggregation, or both, or is free of extracellular domains 3 and 4. Also provided are pharmaceutical compositions comprising the compositions, polypeptides, nucleic acid systems and nucleic acid molecules encoding the polypeptides of the compositions of the invention, and methods of using the compositions or polypeptides for treatment and for determining the suitability of treatment; and methods of making the compositions or proteins.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.